undamentalytics Newsletter
Sign in

Medpace Holdings, Inc. cash flow statement

In fiscal 2025, Medpace Holdings, Inc.'s operations generated $713m of cash; it spent $31.4m on capital projects, leaving free cash flow of $682m. It returned $917m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations869297157202259263388433609713723
Depreciation and amortisation6799812161924282727
Stock-based pay2210462114142121263522
Capital spending61412161831283737373155
Free cash flow797886141184227235351397572682668
Free cash flow after stock pay576881134163214221330376547647645
Share buybacks00156009862848144170917295
Shares issued117400————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: FTRE vs MEDPBIO vs MEDPBRKR vs MEDPMEDP vs QGEN

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Medpace Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 23, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Medpace Holdings, Inc.